ECJ judgement means generics firms cannot rely on pre-EU data
This article was originally published in SRA
Executive Summary
A ruling by the European Court of Justice in a case that dealt with complex issues surrounding the data exclusivity granted to medicinal products has major implications for the pharmaceutical industry. The ruling essentially means that a product that was initially granted a marketing authorisation under national rules and which was never updated to meet current EU legislative requirements cannot be used as a reference medicinal product for the approval of a generic version containing the same active substance.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.